health

The biggest shift this week is the publication of the first human safety and early-efficacy observations from the dopamine gene therapy trial OXB-102 (also called Axo-Lenti-PD). Where last period's digest described the gene-therapy pipeline in general terms, there is now published Phase 1/2 data to point to. The Movement Disorders paper covers an open-label trial in which a viral vector delivers genes for dopamine synthesis directly into the striatum — aiming to rebuild the brain's own production machinery rather than replacing the dopamine signal from outside. Safety signals were acceptable and early motor effects were observed. This is a small, open-label Phase 1/2 study with no control arm, so the efficacy signal is exploratory, not conclusive. Nonetheless, it is human data, and it matters: gene therapy for Parkinson's has now cleared the first real hurdle. Nothing to act on today, but worth following if you are tracking disease-modification options.

A major disease-modification bet fails

In direct contrast, Biogen and Denali have halted their BIIB122 trial — one of the largest and most closely watched LRRK2-inhibitor studies in idiopathic (non-genetic) Parkinson's. The drug did not slow progression. This is a significant setback: LRRK2 inhibition had been a leading disease-modification hypothesis, and this trial was well-powered and well-funded. The failure does not close the door on LRRK2 as a target in patients who carry the LRRK2 gene variant — a different question — but it tells us that blocking this pathway does not benefit the broader PD population in the way researchers hoped. Adjust expectations accordingly if this trial was on your watch list.

Why your levodopa coverage has hidden gaps — and what adaptive DBS is trying to do about it

A Movement Disorders essay maps what the authors call the "dark matter" of levodopa pharmacodynamics: the substantial share of motor fluctuation and wearing-off that cannot be explained by blood levels or dosing schedules alone. The paper does not offer a clinical fix, but it articulates clearly why optimising timing and dose only goes so far — and it frames the problem that brain stimulation is trying to solve. A companion position paper on adaptive DBS argues that spatial optimisation of electrode placement must come before tuning the stimulation pattern in real time — a practical sequencing point for anyone approaching DBS programming. Together, these are expert opinion and modelling, not new trial results, but they are useful frames for conversations with a movement disorder specialist about unexplained fluctuations.

Focused ultrasound: from specialist procedure to growing evidence base

Multiple items this week converge on focused ultrasound — a non-invasive procedure that uses sound waves to ablate or modulate specific brain targets. A neurologist interview describes it as a likely next major treatment step, and a detailed patient account from a Spanish patient describes relief from severe, previously refractory pain. A non-invasive ultrasound headset for tremor is also reported showing immediate results. The evidence varies — some of this is anecdote, some is device reporting, not peer-reviewed trials — but the clinical interest is clearly building. Focused ultrasound for tremor is approved in several countries; for other indications, it is still mostly in specialist centres or trials. If tremor or pain is inadequately controlled, it is a reasonable question for your movement disorder neurologist.

Ayahuasca without the hallucinations: a new mechanism for an old compound

Researchers have shown in animal models that ayahuasca's apparent benefits in Parkinson's — anti-inflammatory and neuroprotective effects — can be separated from its hallucinogenic action, potentially through non-psychedelic compounds in the brew such as harmine. This opens a path toward pharmaceutical derivatives that could be tested without the psychedelic liability. This is preclinical (animal study) and nowhere near the clinic. Worth tracking for those following the plant-medicine pipeline; nothing actionable now.

Practical note: heat worsens symptoms

As summer begins in the northern hemisphere, a practical reminder circulated this week: high temperatures can worsen both motor and non-motor symptoms in Parkinson's — including slowing medication absorption, worsening fatigue, and increasing fall risk. Plan outdoor activities during cooler hours, maintain hydration, and be alert to symptom changes in heatwaves. Expert opinion and clinical experience.

AI as assistive tool for creative expression

Several stories this week follow musicians with Parkinson's who are using AI composition tools to continue making music after motor symptoms made playing instruments too difficult. This is an emerging assistive-technology space with no clinical evidence to evaluate, but worth knowing exists for patients for whom creative expression is part of wellbeing.